These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25908175)

  • 1. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity.
    Duong MN; Cleret A; Matera EL; Chettab K; Mathé D; Valsesia-Wittmann S; Clémenceau B; Dumontet C
    Breast Cancer Res; 2015 Apr; 17(1):57. PubMed ID: 25908175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.
    Yamauchi C; Fujii S; Kimura T; Kuwata T; Wada N; Mukai H; Matsumoto N; Fukayama M; Ochiai A
    Int J Cancer; 2011 May; 128(9):2125-37. PubMed ID: 21387286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
    Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
    Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
    Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
    Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.
    Tóth G; Szöőr Á; Simon L; Yarden Y; Szöllősi J; Vereb G
    MAbs; 2016 Oct; 8(7):1361-1370. PubMed ID: 27380003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer.
    Miura D; Yoneyama K; Furuhata Y; Shimizu K
    J Nippon Med Sch; 2014; 81(4):211-20. PubMed ID: 25186575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
    Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
    Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
    Varchetta S; Gibelli N; Oliviero B; Nardini E; Gennari R; Gatti G; Silva LS; Villani L; Tagliabue E; Ménard S; Costa A; Fagnoni FF
    Cancer Res; 2007 Dec; 67(24):11991-9. PubMed ID: 18089830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.
    Zheng G; Guo Z; Li W; Xi W; Zuo B; Zhang R; Wen W; Yang AG; Jia L
    Signal Transduct Target Ther; 2021 Jun; 6(1):236. PubMed ID: 34158475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity.
    Du R; Zhang X; Lu X; Ma X; Guo X; Shi C; Ren X; Ma X; He Y; Gao Y; Liu Y
    Drug Resist Updat; 2023 May; 68():100947. PubMed ID: 36812747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HER2 Cancer-Specific mAb, H
    Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Kato Y
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39125956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
    Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H
    J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
    Eitler J; Rackwitz W; Wotschel N; Gudipati V; Murali Shankar N; Sidorenkova A; Huppa JB; Ortiz-Montero P; Opitz C; Künzel SR; Michen S; Temme A; Loureiro LR; Feldmann A; Bachmann M; Boissel L; Klingemann H; Wels WS; Tonn T
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing.
    Kute TE; Savage L; Stehle JR; Kim-Shapiro JW; Blanks MJ; Wood J; Vaughn JP
    Cancer Immunol Immunother; 2009 Nov; 58(11):1887-96. PubMed ID: 19340424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Flow Cytometry.
    van der Haar Àvila I; Marmol P; Cany J; Kiessling R; Pico de Coaña Y
    Methods Mol Biol; 2019; 1913():181-194. PubMed ID: 30666607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer.
    Masuda T; Fujimoto H; Teranaka R; Kuroda M; Aoyagi Y; Nagashima T; Sangai T; Takada M; Nakagawa A; Kubota Y; Yokote K; Ohtsuka M
    Breast Cancer Res Treat; 2020 Apr; 180(3):625-634. PubMed ID: 32124135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients.
    Suzuki E; Kataoka TR; Hirata M; Kawaguchi K; Nishie M; Haga H; Toi M
    BMC Cancer; 2015 Feb; 15():39. PubMed ID: 25655677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.